Akebia Therapeutics Inc (NASDAQ:AKBA) has earned an average rating of “Buy” from the nine brokerages that are covering the firm. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $14.80.

A number of equities research analysts recently weighed in on AKBA shares. JMP Securities reissued a “market perform” rating and set a $16.00 price target on shares of Akebia Therapeutics in a research note on Thursday, August 11th. Credit Suisse Group AG reissued a “hold” rating and set a $8.00 price target on shares of Akebia Therapeutics in a research note on Tuesday, August 9th. Zacks Investment Research downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 11th. HC Wainwright reissued a “buy” rating on shares of Akebia Therapeutics in a research note on Tuesday, August 23rd. Finally, Aegis started coverage on shares of Akebia Therapeutics in a research note on Tuesday, November 15th. They set a “buy” rating and a $18.00 price target for the company.

Akebia Therapeutics (NASDAQ:AKBA) opened at 8.98 on Friday. Akebia Therapeutics has a 1-year low of $7.00 and a 1-year high of $13.20. The firm’s market cap is $164.33 million. The company has a 50-day moving average of $8.28 and a 200-day moving average of $8.37.

Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.09) by $0.13. During the same quarter last year, the business earned ($0.47) EPS. Analysts predict that Akebia Therapeutics will post ($3.53) earnings per share for the current year.

A number of large investors have recently modified their holdings of AKBA. Alliancebernstein L.P. bought a new position in Akebia Therapeutics during the second quarter valued at $105,000. BlackRock Advisors LLC boosted its position in Akebia Therapeutics by 4.3% in the second quarter. BlackRock Advisors LLC now owns 16,531 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 676 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Akebia Therapeutics during the second quarter valued at $147,000. American International Group Inc. boosted its position in Akebia Therapeutics by 44.9% in the second quarter. American International Group Inc. now owns 20,684 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 6,405 shares during the period. Finally, Highbridge Capital Management LLC bought a new position in Akebia Therapeutics during the third quarter valued at $195,000. 51.79% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Akebia Therapeutics Inc (AKBA) Receives Average Rating of “Buy” from Brokerages” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/23/akebia-therapeutics-inc-akba-receives-average-rating-of-buy-from-brokerages.html.

About Akebia Therapeutics

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.

5 Day Chart for NASDAQ:AKBA

Receive News & Stock Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related stocks with our FREE daily email newsletter.